Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs.
Fiche publication
Date publication
août 2018
Journal
Intensive care medicine experimental
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle, Dr REPPEL Loïc
Tous les auteurs :
Laroye C, Lemarié J, Boufenzer A, Labroca P, Cunat L, Alauzet C, Groubatch F, Cailac C, Jolly L, Bensoussan D, Reppel L, Gibot S
Lien Pubmed
Résumé
Septic shock is the leading cause of death in intensive care units. The pathophysiological complexity of this syndrome contributes to an absence of specific treatment. Several preclinical studies in murine models of septic shock have shown improvements to organ injury and survival after administration of mesenchymal stem cells (MSCs). To better mimic a clinical approach in humans, we investigated the impact of randomized controlled double-blind administration of clinical-grade umbilical cord-derived MSCs to a relevant pig model of septic shock.
Mots clés
Clinical-grade, Mesenchymal stem cells, Septic shock, Umbilical cord
Référence
Intensive Care Med Exp. 2018 Aug 8;6(1):24